[go: up one dir, main page]

MA27926A1 - Derives de quinoline et de quinazoline presentant une affinite vis-a-vis des recepteurs du type 5ht1 - Google Patents

Derives de quinoline et de quinazoline presentant une affinite vis-a-vis des recepteurs du type 5ht1

Info

Publication number
MA27926A1
MA27926A1 MA28738A MA28738A MA27926A1 MA 27926 A1 MA27926 A1 MA 27926A1 MA 28738 A MA28738 A MA 28738A MA 28738 A MA28738 A MA 28738A MA 27926 A1 MA27926 A1 MA 27926A1
Authority
MA
Morocco
Prior art keywords
quinoline
affinity
quinazoline derivatives
receptors
5yht1
Prior art date
Application number
MA28738A
Other languages
English (en)
Inventor
Bergauer Markus
Bertani Barbara
Biagetti Matteo
Mark Bromidge Steven
Falchi Alessandro
Philip Leslie Colin
Merlo Giancarlo
Antonia Pizzi Domenica
Rinaldi Marilisa
Piero Stasi Luigi
Tibasco Jessica
Kuok Keong Vong Antonio
Edward Ward Simon
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of MA27926A1 publication Critical patent/MA27926A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C04—CEMENTS; CONCRETE; ARTIFICIAL STONE; CERAMICS; REFRACTORIES
    • C04B—LIME, MAGNESIA; SLAG; CEMENTS; COMPOSITIONS THEREOF, e.g. MORTARS, CONCRETE OR LIKE BUILDING MATERIALS; ARTIFICIAL STONE; CERAMICS; REFRACTORIES; TREATMENT OF NATURAL STONE
    • C04B35/00—Shaped ceramic products characterised by their composition; Ceramics compositions; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
    • C04B35/622—Forming processes; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
    • C04B35/626—Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B
    • C04B35/63—Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B using additives specially adapted for forming the products, e.g.. binder binders
    • C04B35/632—Organic additives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Manufacturing & Machinery (AREA)
  • Neurosurgery (AREA)
  • Ceramic Engineering (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Inorganic Chemistry (AREA)
  • Materials Engineering (AREA)
  • Structural Engineering (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Dérivés de quinoléine et quinazoline présentant une affinité pour les récepteurs du type 5YHT1 Il est proposé des composés de formule (I) et leurs sels pharmaceutiquement acceptables : dans lesquels R1, m, X, R2, n, W, p, Y, Z, R3, R4, R5 et q répondent aux définitions mentionnées dans la description. Il est révélé également des procédés pour leur préparation et leurs utilisations en thérapeutique, en particulier pour des troubles du SNC tels que la dépression ou l'anxiété.
MA28738A 2003-07-18 2006-01-18 Derives de quinoline et de quinazoline presentant une affinite vis-a-vis des recepteurs du type 5ht1 MA27926A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0316915.8A GB0316915D0 (en) 2003-07-18 2003-07-18 Compounds

Publications (1)

Publication Number Publication Date
MA27926A1 true MA27926A1 (fr) 2006-06-01

Family

ID=27764115

Family Applications (1)

Application Number Title Priority Date Filing Date
MA28738A MA27926A1 (fr) 2003-07-18 2006-01-18 Derives de quinoline et de quinazoline presentant une affinite vis-a-vis des recepteurs du type 5ht1

Country Status (28)

Country Link
US (5) US7279481B2 (fr)
EP (3) EP1876174B1 (fr)
JP (1) JP2006528146A (fr)
KR (1) KR20060041242A (fr)
CN (1) CN100441571C (fr)
AR (1) AR046394A1 (fr)
AT (2) ATE389637T1 (fr)
AU (1) AU2004263268B2 (fr)
BR (1) BRPI0412695A (fr)
CA (1) CA2532452A1 (fr)
CY (1) CY1107974T1 (fr)
DE (2) DE602004024141D1 (fr)
DK (1) DK1646613T3 (fr)
ES (2) ES2336148T3 (fr)
GB (1) GB0316915D0 (fr)
HR (1) HRP20080226T3 (fr)
IL (1) IL173036A0 (fr)
IS (1) IS2744B (fr)
MA (1) MA27926A1 (fr)
MX (1) MXPA06000716A (fr)
NO (1) NO20060774L (fr)
NZ (1) NZ544586A (fr)
PL (1) PL1646613T3 (fr)
PT (1) PT1646613E (fr)
RU (1) RU2402533C2 (fr)
SI (1) SI1646613T1 (fr)
TW (1) TW200521115A (fr)
WO (1) WO2005014552A1 (fr)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE424825T1 (de) 2001-07-20 2009-03-15 Psychogenics Inc Behandlung von hyperaktivitätsstörungen und aufmerksamkeitsdefiziten
GB0316915D0 (en) * 2003-07-18 2003-08-20 Glaxo Group Ltd Compounds
NZ552404A (en) * 2004-06-17 2010-04-30 Cytokinetics Inc Compounds, compositions and methods
KR100817538B1 (ko) * 2006-07-05 2008-03-27 한국화학연구원 신규 치환된―１ｈ―퀴나졸린―２,４―디온 유도체, 이의제조방법 및 이를 함유하는 약학적 조성물
CA2673481A1 (fr) * 2006-12-19 2008-06-26 University Of Virginia Patent Foundation Effets combines de topiramate/ondansetrone sur la consommation d'alcool
WO2008095086A2 (fr) * 2007-01-31 2008-08-07 University Of Virginia Patent Foundation Topiramate plus naltrexone pour le traitement de troubles addictifs
ES2359170T3 (es) 2007-07-19 2011-05-19 Laboratorios Del Dr. Esteve S.A. Compuestos tetrahidro-quinolín-sulfonamida sustituidos, su preparación y uso como medicamentos.
US20110065628A1 (en) * 2007-08-27 2011-03-17 University Of Virginia Patent Foundation Medication Combinations for the Treatment of Alcoholism and Drug Addiction
CA2716498C (fr) 2008-02-28 2020-12-22 University Of Virginia Patent Foundation Gene du transporteur de la serotonine et traitement de l'alcoolisme
CA2722326A1 (fr) 2008-04-24 2009-10-29 Incyte Corporation Composes macrocycliques et leur utilisation a titre d'inhibiteurs de kinase
EP2116205B1 (fr) * 2008-05-06 2010-12-29 BIEDERMANN MOTECH GmbH Implant en forme de tige, en particulier pour la stabilisation dynamique de la colonne vertébrale
US20100298397A1 (en) * 2009-05-19 2010-11-25 Singh Nikhilesh N Method of treatment of obsessive compulsive disorder with ondansetron
CN101671336B (zh) 2009-09-23 2013-11-13 辽宁利锋科技开发有限公司 芳杂环并嘧啶衍生物和类似物及其制备方法和用途
EP2308850A1 (fr) * 2009-10-06 2011-04-13 Laboratorios Del. Dr. Esteve, S.A. Dérivés d'éthylamine-phényle substitué d'hétérocyclyle, leur préparation et utilisation en tant que médicaments
IL278149B2 (en) 2010-07-02 2024-03-01 Univ Virginia Patent Foundation Molecular genetic approach to treatment and diagnosis of alcohol and drug dependence
GEP201606559B (en) * 2011-08-09 2016-10-25 Takeda Pharmaceuticals Co Cyclopropaneamine compound
WO2013036721A1 (fr) 2011-09-09 2013-03-14 University Of Virginia Patent Foundation Approche génétique moléculaire pour le traitement et le diagnostic d'une dépendance à l'alcool et d'une pharmacodépendance
GB201117313D0 (en) 2011-10-07 2011-11-16 Gt Biolog Ltd Bacterium for use in medicine
WO2013169964A1 (fr) * 2012-05-09 2013-11-14 Sunovion Pharmaceuticals Inc. Composés hétéroaryles et leurs procédés d'utilisation
CN103508927A (zh) * 2012-06-25 2014-01-15 天津药物研究院 一种2-甲磺酰氨基二苯醚的制备方法
CN105051005B (zh) 2012-10-12 2017-06-13 武田药品工业株式会社 环丙胺化合物及其用途
GB201306536D0 (en) 2013-04-10 2013-05-22 Gt Biolog Ltd Polypeptide and immune modulation
MX2016006482A (es) 2013-11-20 2016-12-09 Sanwa Kagaku Kenkyusho Co Derivado novedoso de 3-azabiciclo[3.1.0]hexano y uso del mismo para proposito medico.
NZ725262A (en) 2014-04-11 2023-01-27 Takeda Pharmaceuticals Co Cyclopropanamine compound and use thereof
FR3028527A1 (fr) 2014-11-13 2016-05-20 Pivert Identification de facteurs de transcription de yarrowia lipolytica
WO2016075314A1 (fr) 2014-11-13 2016-05-19 Institut National De La Recherche Agronomique Identification de facteurs de transcription de yarrowia lipolytica affectant la production de proteines
HUE035569T2 (en) 2014-12-23 2018-05-28 4D Pharma Res Ltd Bacteroides thetaiotaomicron strain and its use in reducing inflammation
KR20170091157A (ko) 2014-12-23 2017-08-08 4디 파마 리서치 리미티드 피린 폴리펩티드 및 면역 조정
LT3360559T (lt) 2015-06-15 2019-12-27 4D Pharma Research Limited Kompozicijos, apimančios bakterijų kamienus
ES2753779T3 (es) 2015-06-15 2020-04-14 4D Pharma Res Ltd Blautia stercosis y wexlerae para la utilización en el tratamiento de enfermedades inflamatorias y autoinmunes
MA41060B1 (fr) 2015-06-15 2019-11-29 4D Pharma Res Ltd Compositions comprenant des souches bactériennes
MA41010B1 (fr) 2015-06-15 2020-01-31 4D Pharma Res Ltd Compositions comprenant des souches bactériennes
HUE045413T2 (hu) 2015-06-15 2019-12-30 4D Pharma Res Ltd Baktériumtörzseket tartalmazó készítmények
CN108513545B (zh) 2015-11-20 2020-11-03 4D制药研究有限公司 包含细菌菌株的组合物
GB201520497D0 (en) 2015-11-20 2016-01-06 4D Pharma Res Ltd Compositions comprising bacterial strains
GB201612191D0 (en) 2016-07-13 2016-08-24 4D Pharma Plc Compositions comprising bacterial strains
SG11201807195VA (en) 2016-03-04 2018-09-27 4D Pharma Plc Compositions comprising bacterial blautia strains for treating visceral hypersensitivity
TW201821093A (zh) 2016-07-13 2018-06-16 英商４Ｄ製藥有限公司 包含細菌菌株之組合物
GB201621123D0 (en) 2016-12-12 2017-01-25 4D Pharma Plc Compositions comprising bacterial strains
HUE054164T2 (hu) 2017-05-22 2021-08-30 4D Pharma Res Ltd Baktériumtörzseket tartalmazó készítmények
JP6978514B2 (ja) 2017-05-24 2021-12-08 フォーディー ファーマ リサーチ リミテッド4D Pharma Research Limited 細菌株を含む組成物
ES2855701T3 (es) 2017-06-14 2021-09-24 4D Pharma Res Ltd Composiciones que comprenden cepas bacterianas
SMT202000695T1 (it) 2017-06-14 2021-01-05 4D Pharma Res Limited Composizioni comprendenti ceppi batterici
JP2020523326A (ja) 2017-06-14 2020-08-06 フォーディー ファーマ リサーチ リミテッド４Ｄ Ｐｈａｒｍａ Ｒｅｓｅａｒｃｈ Ｌｉｍｉｔｅｄ 細菌株を含む組成物
CN108047143A (zh) * 2017-12-18 2018-05-18 刘凤娟 一种用于治疗功能性胃肠病的5-羟色胺受体拮抗剂的合成方法
WO2020006018A1 (fr) 2018-06-27 2020-01-02 Bristol-Myers Squibb Company Composés de naphtyridinone substitués utiles en tant qu'activateurs de lymphocytes t
US11866430B2 (en) 2018-06-27 2024-01-09 Bristol-Myers Squibb Company Naphthyridinone compounds useful as T cell activators
AR119821A1 (es) 2019-08-28 2022-01-12 Bristol Myers Squibb Co Compuestos de piridopirimidinonilo sustituidos útiles como activadores de células t
MX2022007130A (es) 2019-12-23 2022-07-11 Bristol Myers Squibb Co Derivados de piperazina sustituidos utiles como activadores de celulas t.
AR120823A1 (es) 2019-12-23 2022-03-23 Bristol Myers Squibb Co Compuestos bicíclicos sustituidos útiles como activadores de células t
ES3038401T3 (en) 2019-12-23 2025-10-13 Bristol Myers Squibb Co Substituted quinazolinyl compounds useful as t cell activators
CN118308475B (zh) * 2024-03-18 2024-11-26 安徽医科大学第一附属医院 Htr1b作为胚胎发育停滞的诊断标志物和治疗靶点方面的应用

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2641602A (en) 1950-11-29 1953-06-09 Eastman Kodak Co 1, 8-dihydroxy-5-nitro-4-hydroxyethylphenyl aminoanthraquinone compounds
US3975525A (en) 1971-06-07 1976-08-17 Boehringer Ingelheim Gmbh N-[4'-Imidazolidinon-(2)-yl-phenethyl]-N'-pyridyl-piperazines and salts thereof
US3937708A (en) 1971-06-07 1976-02-10 Boehringer Ingelheim Gmbh N-phenyl-imidazolidine-1-ones
US3992537A (en) 1971-06-07 1976-11-16 Boehringer Ingelheim Gmbh Pharmaceutical compositions containing an N-phenyl-imidazolidine-2-one and method of use
JPS5883677A (ja) 1981-11-11 1983-05-19 Otsuka Pharmaceut Co Ltd カルボスチリル誘導体
US4891275A (en) * 1982-10-29 1990-01-02 Norsk Hydro A.S. Aluminum shapes coated with brazing material and process of coating
JPS6354363A (ja) 1986-08-26 1988-03-08 Ss Pharmaceut Co Ltd キノリン誘導体
FI95572C (fi) 1987-06-22 1996-02-26 Eisai Co Ltd Menetelmä lääkeaineena käyttökelpoisen piperidiinijohdannaisten tai sen farmaseuttisen suolan valmistamiseksi
US4933447A (en) 1987-09-24 1990-06-12 Ss Pharmaceutical Co., Ltd. Quinoline derivatives
US4891375A (en) 1988-01-13 1990-01-02 Pfizer Inc. Arylpiperazinyl-alkylene-phenyl-heterocyclic compounds
JP2777159B2 (ja) 1988-12-22 1998-07-16 エーザイ株式会社 環状アミン誘導体を含有する医薬
AU645681B2 (en) * 1991-05-02 1994-01-20 John Wyeth & Brother Limited Piperazine derivatives
NZ240863A (en) * 1991-09-11 1995-04-27 Mcneilab Inc Substituted 4-aryl piperidine and 4-aryl piperazine derivatives, preparation and pharmaceutical compositions thereof
GB9300194D0 (en) 1993-01-06 1993-03-03 Wyeth John & Brother Ltd Piperazine derivatives
GB9300195D0 (en) 1993-01-06 1993-03-03 Wyeth John & Brother Ltd Piperazine derivatives
GB9308725D0 (en) 1993-04-27 1993-06-09 Wyeth John & Brother Ltd Piperazine derivatives
US6225312B1 (en) * 1996-03-29 2001-05-01 Duphar International Research B.V. Piperazine and piperidine compounds
AU2446297A (en) 1996-04-30 1997-11-19 Warner-Lambert Company Substituted piperazines and piperidines as central nervous system agents
GB2312843A (en) 1996-05-07 1997-11-12 Merck & Co Inc Method of treating rheumatoid arthritis
WO1998025617A1 (fr) 1996-12-13 1998-06-18 Merck & Co., Inc. Arylpiperazines substituees utilisees comme modulateurs de l'activite du recepteur de la chemokine
ATE253058T1 (de) 1997-09-02 2003-11-15 Duphar Int Res Piperidin- und piperazin derivate als 5-ht1- rezeptor-agonisten
EP0900792B1 (fr) * 1997-09-02 2003-10-29 Duphar International Research B.V Dérivés de pipéridine et de pipérazine comme agonistes du récepteur 5-HT1
EE04588B1 (et) 1997-10-27 2006-02-15 Neurosearch A/S Heteroarüüldiasatsükloalkaanid kui atsetüülkoliini nikotiinretseptorite kolinergilised ligandid, nende kasutamine ravimitena ning neid sisaldav farmatseutiline kompositsioon
EP1047691A1 (fr) * 1997-12-12 2000-11-02 Smithkline Beecham Plc Derives de quinoleinepiperazine et de quinoleinepiperidine, leur preparation et leur utilisation en tant qu'antagonistes combines des recepteurs 5-ht1a, 5-ht1b et 5-ht1d
UA62015C2 (en) * 1998-12-28 2003-12-15 Pfizer Prod Inc Benzoizoxazol derivatives, a pharmaceutical composition (variants) based thereon (variants) and a method for treatment (variants)
KR20010085555A (ko) 1999-06-24 2001-09-07 히라이 가쯔히꼬 아드레날린 알파1비 수용체 길항약
DE60017446T2 (de) 1999-11-05 2006-03-02 Smithkline Beecham P.L.C., Brentford Isochinolin- und Chinazolinderivate mit kombinierter 5-HT1A-, 5-HT1B- und 5-HT1D- Rezeptoraffinität
CA2426706A1 (fr) 2000-10-26 2002-05-02 Smithkline Beecham P.L.C. Derives de benzoxazinone, leur preparation et utilisation
CA2364211A1 (fr) 2000-12-05 2002-06-05 Phillip Branch Chappell Traitement combine de la depression, de l'anxiete et de la psychose
GB0106419D0 (en) * 2001-03-15 2001-05-02 Smithkline Beecham Plc Novel compounds
UY27304A1 (es) 2001-05-24 2002-12-31 Avanir Pharmaceuticals Inhibidores del factor inhibidor de la migración de los macrófagos y métodos para su identificación
GB0203804D0 (en) 2002-02-18 2002-04-03 Glaxo Group Ltd Compounds
GB0224084D0 (en) 2002-10-16 2002-11-27 Glaxo Group Ltd Novel compounds
EP1562919A1 (fr) 2002-11-08 2005-08-17 Warner-Lambert Company LLC Derives de piperazine phenylalkyles et pyridylalkyles
GB0227240D0 (en) 2002-11-21 2002-12-31 Glaxo Group Ltd Compounds
TW200418829A (en) 2003-02-14 2004-10-01 Avanir Pharmaceutics Inhibitors of macrophage migration inhibitory factor and methods for identifying the same
US6759435B1 (en) * 2003-07-03 2004-07-06 A.P. Group Inc. Antidepressant drugs and methods
GB0316915D0 (en) 2003-07-18 2003-08-20 Glaxo Group Ltd Compounds
US20050124625A1 (en) 2003-10-21 2005-06-09 Salvati Mark E. Piperazine derivatives and their use as modulators of nuclear hormone receptor function
WO2005087742A1 (fr) 2004-03-08 2005-09-22 Exelixis, Inc. Modulateurs metaboliques de kinases et leurs procedes d'utilisation en tant que pesticides
BRPI0508481A (pt) 2004-03-10 2007-07-31 Altana Pharma Ag hidróxi-6-fenilenantridinas amido-substituìdas e seu uso como inibidores de pde4
PE20060653A1 (es) 2004-08-31 2006-09-27 Glaxo Group Ltd Derivados triciclicos condensados como moduladores del receptor 5-ht1

Also Published As

Publication number Publication date
US20070167423A1 (en) 2007-07-19
PT1646613E (pt) 2008-06-19
EP2145622A1 (fr) 2010-01-20
JP2006528146A (ja) 2006-12-14
IL173036A0 (en) 2006-06-11
ES2336148T3 (es) 2010-04-08
RU2006104993A (ru) 2006-08-10
SI1646613T1 (sl) 2008-08-31
US7279481B2 (en) 2007-10-09
PL1646613T3 (pl) 2008-08-29
AU2004263268A1 (en) 2005-02-17
IS2744B (is) 2011-08-15
US20080280919A1 (en) 2008-11-13
AR046394A1 (es) 2005-12-07
GB0316915D0 (en) 2003-08-20
IS8304A (is) 2006-02-15
HK1089438A1 (en) 2006-12-01
EP1876174B1 (fr) 2009-11-11
DE602004024141D1 (de) 2009-12-24
US20060229312A1 (en) 2006-10-12
KR20060041242A (ko) 2006-05-11
US20100204273A1 (en) 2010-08-12
CN100441571C (zh) 2008-12-10
US20090312546A1 (en) 2009-12-17
RU2402533C2 (ru) 2010-10-27
ES2302543T3 (es) 2008-07-16
TW200521115A (en) 2005-07-01
DE602004012564T2 (de) 2009-04-30
EP1646613B1 (fr) 2008-03-19
ATE389637T1 (de) 2008-04-15
NZ544586A (en) 2009-05-31
DK1646613T3 (da) 2008-07-14
BRPI0412695A (pt) 2006-10-03
HRP20080226T3 (en) 2008-06-30
AU2004263268B2 (en) 2010-12-16
CA2532452A1 (fr) 2005-02-17
DE602004012564D1 (de) 2008-04-30
US7732600B2 (en) 2010-06-08
EP1646613A1 (fr) 2006-04-19
US7459456B2 (en) 2008-12-02
US7592346B2 (en) 2009-09-22
MXPA06000716A (es) 2006-03-30
NO20060774L (no) 2006-04-06
WO2005014552A1 (fr) 2005-02-17
CY1107974T1 (el) 2013-09-04
ATE448205T1 (de) 2009-11-15
CN1852896A (zh) 2006-10-25
EP1876174A1 (fr) 2008-01-09

Similar Documents

Publication Publication Date Title
MA27926A1 (fr) Derives de quinoline et de quinazoline presentant une affinite vis-a-vis des recepteurs du type 5ht1
MA29772B1 (fr) Benzimidazoles substitues et procedes de preparation
EA200500342A1 (ru) Гетероциклические замещённые пиперазины для лечения шизофрении
TNSN04151A1 (fr) Derives de nicotinamide utiles comme inhibiteurs de pde4
TN2010000130A1 (fr) Derives de quinazolinedione, leur preparation et leurs applications therapeutiques
MA27569A1 (fr) Derives de pyrrolo-pyrazole substitues servant d'inhibiteurs de kinases
MA30289B1 (fr) Dérivés d'amines
MA29170B1 (fr) Derives puriniques agissant comme des agonistes du recepteur a2a
MEP45308A (en) [1,8]naphthyridin-2-ones and related compounds for the treatment of schizophrenia
DE69331190D1 (de) Überbrückte azabicyclische derivate als substanz p antagonisten
YU45403A (sh) Novi 1,2-difenil-azetidinoni, postupak za njihovu proizvodnju, lekovi koji sadrže ova jedinjenja i njihova primena za lečenje poremećaja u metabolizmu lipida
TNSN05073A1 (fr) Quinazolinones spirocondensees nouvelles et leur utilisation comme inhibiteurs de phosphodiesterase
MA31521B1 (fr) Dérivés de 2,3-dihydrobenzo[1,4] dioxin-2-ylméthyle utilisés en tant qu'antagonistes des alpha2c pour traiter des maladies des systèmes nerveux périphérique et central
EA200500172A1 (ru) Азабициклопроизводные в качестве антагонистов мускариновых рецепторов
IL186777A0 (en) (3,4-dihydro-quinazolin-2-yl) - (2-aryloxy-ethyl) - amines having an activity on the 5 - ht receptor
NZ331060A (en) Quinoxalinediones, preparation and pharmaceutical compositions thereof
AU4038600A (en) 4-substituted quinoline derivatives as nk-3 and/or gaba(a) receptor ligands
MA29566B1 (fr) Composes chimiques
MA27781A1 (fr) 3-fluoro-piperidines comme antagonistes de nmda/nr2b.
MA27930A1 (fr) Derives de nicotinamide utiles comme inhibiteurs de pde4
EA200501593A1 (ru) Азабициклические производные в качестве антагонистов мускаринового рецептора
MA27412A1 (fr) Nouveaux pyrimidine-4,6-dicarboxamides pour l'inhibition selective de collagenases
CY1108837T1 (el) ΝΕΑ ΠΑΡΑΓΩΓΑ ΑΜΙΝΟΠΥΡΙΔΙΝΗΣ ΩΣ ΑΝΤΑΓΩΝΙΣΤΕΣ mGluR5
CY1107362T1 (el) Παραγωγα ιμιδαζολυλιου χρησιμα ως συνδετες υποδοχεων ισταμινης h3
BR0201569A (pt) 4-(2-piridil) piperizinas possuindo uma atividade agonista do receptor 5ht7